# This Week in Cannabis: Clinical Research & Therapeutic Applications > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-clinical-research-therapeutic-applications-march-2026/ > **Published:** 2026-03-16T10:53:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:55-04:00 > **Clinical Summary:** Explore the latest cannabis clinical research therapeutic applications, regulatory updates, and safety monitoring in this March 16, 2026 weekly roundup. --- Weekly RoundupThis week, cannabis coverage focused on regulatory developments, commercial testing technology, and [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into therapeutic applications and safety monitoring.Monday, March 16, 2026 — top 4 across News, Studies, Policy, and Memes News A March 16, 2026 news roundup featuring five cannabis stories, including research on whether cannabis use accelerates mental decline in older adults. [AM News Update: March 16, 2026 →](https://cedclinic.com/cannabis-use-by-older-adults-mental-decline-2026/) Cannabix Technologies has launched a commercial marijuana breath test device that provides rapid, non-invasive detection of cannabis use for clinical and impairment assessment applications. [Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) →](https://cedclinic.com/marijuana-breath-test-technology-workplace-screening/) Avicanna is sponsoring a University of Calgary clinical trial to determine safe and effective THC dosing for therapeutic use in patients. [Avicanna announces sponsorship of University of Calgary THC dose finding clinical trial →](https://cedclinic.com/thc-dosing-clinical-trial-avicanna-sponsorship/) This clinical resource examines cannabis use among teenage and young adult drivers, focusing on safety concerns relevant to pediatric and mental health clinicians. [Driving habits of teens and young adults | National Poll on Children’s Health →](https://cedclinic.com/cannabis-use-among-teen-drivers-safety-risks/) Studies A March 2026 research update summarizing 20 cannabis studies from PubMed, including a phase 3 trial of Cannabis sativa extract for chronic low back pain. [AM Study Update: March 16, 2026 →](https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/) This piece reviews clinical evidence on cannabinoid use in pediatric patients across various medical conditions, noting data quality varies across different study types. [Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/) Research: Cannabinoids in Children → A phase 3 clinical trial tested full-spectrum cannabis extract VER-01 versus placebo in 820 adults with chronic low back pain over 12 weeks, with extended follow-up to one year. [endocannabinoid system clinical research: Cannabis for Back Pain →](https://cedclinic.com/full-spectrum-cannabis-extract-ver-01-back-pain-trial/) A March 2026 research update presenting 20 cannabis studies from PubMed, including a phase 3 trial of Cannabis sativa extract for chronic low back pain. [AM Study Update: March 16, 2026 →](https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/) Policy The DEA temporarily placed bromazolam, a benzodiazepine analog, in Schedule I, as reported in a March 16, 2026 policy update covering 20 federal regulatory items. [AM Policy Update: March 16, 2026 →](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/) The AM Policy Update from March 16, 2026 covers 20 federal regulatory items, including the DEA’s temporary placement of bromazolam into Schedule I of controlled substances. [AM Policy Update: March 16, 2026 →](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/) The DEA temporarily scheduled bromazolam as a Schedule I controlled substance, among 20 federal regulatory updates reported on March 15, 2026. [AM Policy Update: March 15, 2026 →](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) The DEA temporarily placed bromazolam, a benzodiazepine analog, into Schedule I of controlled substances due to emerging safety and abuse concerns. [Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I →](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) Memes This article discusses how cannabis cannabinoid profiles are more important than botanical classifications like indica, sativa, or hybrid varieties. [What kind of tree is this? →](https://cedclinic.com/what-kind-of-tree-is-this/) A clinical anecdote about a patient consultation where discussion of cannabis terpene profiles became overly focused on geographic origin details. [Hello everyone, greetings from Morocco →](https://cedclinic.com/hello-everyone-greetings-from-morocco/) A post asks whether cannabis with visible trichomes but a high leaf-to-flower ratio is worth smoking, questioning the balance between potency indicators and trimming quality. [Settle the debate. Would you smoke this or is it too leafy? →](https://cedclinic.com/settle-the-debate-would-you-smoke-this-or-is-it-too-leafy/) The piece humorously critiques unfounded medical claims about cannabis, specifically calling out the assertion that it cures cancer without scientific evidence. [What’s a stoner opinion that would have you like this? →](https://cedclinic.com/whats-a-stoner-opinion-that-would-have-you-like-this/) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection on Current [Cannabis Medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) Landscape The digest reflects a field in transitional maturity, where legitimate [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on cannabinoid therapeutics, particularly for pain management and dose optimization, now coexists alongside ongoing policy development and emerging detection technologies that will increasingly shape clinical practice documentation and medicolegal considerations. The prominence of regulatory updates and impaired driving surveillance suggests that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioners must now attend equally to evidence-based pharmacology and to the governance frameworks that will govern clinical decision-making and patient safety monitoring. Notably, the inclusion of non-clinical content about product aesthetics underscores the persistent challenge of elevating cannabis medicine discourse beyond consumer-level heuristics toward standardized clinical assessment, despite the field’s demonstrable progress in rigorous Phase 3 trial design and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) research. Clinical Perspective This digest reflects the field’s concurrent focus on clinical evidence development and regulatory infrastructure around cannabis therapeutics. Several items highlight substantive research efforts, including dose-finding trials and phase 3 efficacy data for specific conditions like back pain, alongside emerging diagnostic tools such as breath testing for impairment detection. The inclusion of lighter content suggests the digest casts a wide net, though the core themes center on the tension between accumulating clinical data and the evolving regulatory landscape that will ultimately determine how cannabis products are integrated into evidence-based practice. Cannabis NewsClinical ResearchRegulatory PolicyProduct DevelopmentPublic Health 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+This+Week+in+Cannabis%3A+March+16%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+This+Week+in+Cannabis%3A+March+16%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)](https://cedclinic.com/marijuana-breath-test-technology-workplace-screening/) - [Driving habits of teens and young adults | National Poll on Children’s Health](https://cedclinic.com/cannabis-use-among-teen-drivers-safety-risks/) - [Takeaways from the 2026 South Dakota legislative session](https://cedclinic.com/2026-south-dakota-medical-marijuana-oversight/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [This Week in Cannabis: March 14, 2026](https://cedclinic.com/cannabis-clinical-research-outcomes-2026/) Review the cannabis news and research highlights from March 14, 2026, including regulatory updates and clinical insights. [Read More](https://cedclinic.com/cannabis-clinical-research-outcomes-2026/) [Endocannabinoid System Clinical Research: Pain Management Trial](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) Explore detailed findings from clinical trials on the endocannabinoid system’s role in pain management. [Explore Study](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) [AM Study Update: March 17, 2026](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/) Stay updated with the latest [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) studies and [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) from March 17, 2026. [View Update](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).